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Pneumococcal colonization is rarely studied in adults, except 
as part of family surveys. We report the outcomes of coloniza-
tion screening in healthy adults (all were nonsmokers without 
major comorbidities or contact with children aged <5  years) 
who had volunteered to take part in clinical research. Using 
nasal wash culture, we detected colonization in 6.5% of volun-
teers (52 of 795). Serotype 3 was the commonest serotype (10 
of 52 isolates). The majority of the remaining serotypes (35 of 
52 isolates) were nonvaccine serotypes, but we also identified 
persistent circulation of serotypes 19A and 19F. Resistance to at 
least 1 of 6 antibiotics tested was found in 8 of 52 isolates.
Keywords. Drug resistance; microbial; herd immunity; 
nasal washing; Streptococcus pneumoniae.
Colonization with Streptococcus pneumoniae is a key precursor 
to invasive pneumococcal disease (IPD). Colonization is more 
common in children than in adults, and contact with children 
aged <5 years is the main risk factor for adult colonization [1]. 
Pneumococcal conjugate vaccines (PCVs) prevent pediatric 
pneumococcal disease and induce herd protection against vac-
cine serotypes through reductions in colonization in vaccinated 
children and, indirectly, unvaccinated adults [2].
In the United Kingdom, PCV13 (covering serotypes 1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F) was introduced 
to the national immunization program in April 2010, replacing 
PCV7. Longitudinal studies of IPD in the United Kingdom 
have demonstrated serotype replacement following PCV13 
introduction [3]. Serotype replacement has also been demon-
strated in colonization studies of children and their families: 
in 2015–2016, 51.1% of children aged <5 years were colonized 
with nonvaccine-type pneumococci, compared with 1% who 
were colonized with PCV13 serotypes [4]. Parental coloniza-
tion rates were low, with only 2.8% of parents testing positive 
in 2015–2016.
Antimicrobial resistance rates among cases of pneumococ-
cal colonization and disease vary markedly between different 
European countries [5, 6]. Resistance is relatively uncommon in 
the United Kingdom, with <10% of IPD isolates nonsusceptible 
to penicillin [5].
When comparing the serotypes found in IPD and those 
found in childhood colonization, there is some discordance. 
For example, serotype 8 has emerged as the commonest dis-
ease-causing serotype [3], whereas no colonization with sero-
type 8 was identified in the most recent childhood survey [4]. 
In addition, IPD studies have identified incomplete herd pro-
tection in adults against some PCV13 serotypes, particularly 
the highly virulent serotypes 3 and 19A, even though childhood 
colonization with these serotypes was exceedingly rare. This led 
the researchers to conclude that many disease-causing sero-
types have high case-carrier ratios or perhaps only colonize for 
short durations [4]. It also suggests that serotype replacement 
in childhood colonization is an imperfect surrogate for replace-
ment in invasive disease.
Adults without regular contact with children may be less sus-
ceptible to the ecological effects of childhood PCV programs 
and thus could represent a reservoir of vaccine-type pneumo-
cocci [7]. However, studies of such populations are few, typi-
fied by low sampling yield and reliance on molecular detection 
methods, which limit their ability to identify serotypes and 
assess antimicrobial susceptibility [8].
Volunteers for the experimental human pneumococcal col-
onization (EHPC) research program in the Liverpool School 
of Tropical Medicine undergo screening for pneumococcal 
colonization prior to participation. In this article, we use these 
volunteers as a surrogate for the general healthy adult popu-
lation to report colonization rates, serotype distributions, and 
antimicrobial susceptibility profiles in healthy adults over the 
first 7 years of screening.
METHODS
The rationale, methods, and inclusion/exclusion criteria for 
EHPC studies have been previously reported [9]. In brief, the 
studies are open to healthy adults aged ≥18  years, excluding 
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those with important risk factors for pneumococcal disease, 
colonization, or transmission, including cigarette smoking, 
close contact with children aged <5 years, healthcare work or 
care-provider responsibilities, steroid therapy, and respiratory 
or immunosuppressive comorbidities. Recent antibiotic therapy 
(within 2 weeks) and prior pneumococcal vaccination are also 
exclusion criteria. The majority of study recruitment events are 
held in local universities.
All volunteers underwent nasal wash screening for commu-
nity-acquired pneumococcal colonization at their first visit. We 
reviewed all screening nasal wash specimens obtained between 
October 2010 and March 2017. A summary of the original stud-
ies is provided in the Supplementary Materials. All studies were 
approved by the local National Health Service Research Ethics 
Committee, and all participants provided written informed 
consent.
Nasal washes were performed as previously described [9]. In 
brief, 5 mL of 0.9% sodium chloride solution was introduced 
by a syringe into the nose, where it was held for a few seconds 
before being expelled into a sterile container. The participants 
were advised to occlude their pharynx (eg, by pressing their 
tongue against their hard palate) during the procedure, which 
was repeated twice in each nostril, resulting in the use of 20 mL 
of saline. Nasal wash samples were transported to the labora-
tory within 1 hour of collection, where they were plated on gen-
tamicin/blood agar and incubated overnight at 37°C with 5% 
CO2. Community-acquired pneumococcal colonization was 
defined as the identification of S. pneumoniae by using standard 
microbiological techniques, with serogroup identified by the 
latex agglutination test. Where required, the serotype was con-
firmed using the Senti-SP v1.6 molecular serotyping microarray 
(BUGS Bioscience) as previously described [10]. We tested all 
isolates for susceptibility to penicillin, clarithromycin, dox-
ycycline, levofloxacin, trimethoprim-sulfamethoxazole, and 
vancomycin, using disk diffusion and the Etest (bioMérieux, 
Basingstoke, United Kingdom), following the recommenda-
tions and clinical breakpoints of the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST, version 7.1 
[11]; Supplementary Materials). Zones of inhibition were meas-
ured by 2 independent reviewers, and all resistant isolates were 
tested a second time, for confirmation. We used meningitis 
breakpoints when interpreting penicillin minimum inhibitory 
concentrations.
For purposes of analysis, we assumed that maximal vaccine 
coverage of children aged <5  years with the primary series 
of PCV13 was achieved 5  years after its introduction [3]. We 
compared the proportion of individuals who were colonized, 
the proportion who were colonized with PCV13 serotypes, and 
the proportion of isolates displaying antibiotic-resistant pheno-
types before and after 1 April 2015 (the early and late periods, 
respectively), by χ2 analysis or the Fisher exact test where appro-
priate, using SPSS version 24 (IBM, New York, NY).
RESULTS
A total of 795 healthy volunteers met the inclusion criteria and 
underwent nasal wash screening (Table 1). The median age was 
21 years (interquartile range, 20–23 years), and 452 (57%) were 
female. Pneumococcal colonization was detected in 52 partici-
pants (6.5%; 95% confidence interval [CI], 5.0%–8.5%).
We identified PCV13 serotypes in 17 of 52 (32.7%; Figure 
1 and Supplementary Table 3). Serotype 3 was the common-
est isolate (10 of 52 isolates); the next most common vaccine 
types were 19A and 19F (3 isolates each). The most common 
nonvaccine types were 23B (5 isolates) and 8, 11A, 35F, and 37 
(4 isolates each). Colonization rates were not significantly dif-
ferent between the early and late periods (24 of 368 [6.5%] and 
28 of 427 [6.6%], respectively; P = .98). Among colonized par-
ticipants, 8 of 24 (33.3%) were carrying PCV13 serotypes before 
1 April 2015, compared with 9 of 28 (32.1%) carrying PCV13 
serotypes afterward (P = .93).
We identified resistance to at least 1 antibiotic in 8 of 52 iso-
lates (15.4%; 95% CI, 8.0%–27.5%; Supplementary Figure 1 
and Supplementary Table 4). The majority of resistant isolates 
(6 of 8) were nonvaccine types. The highest rate of resistance 
Table 1. Demographic Characteristics of Participants
 Non-colonized (n = 743) Colonized (n = 52) Total
Age, y, median (IQR) 21 (20–23) 21 (19–23) 21 (20–23)
Female sex, no. (%) 428 (57.6) 24 (46.2) 452 (56.9)
Year of screen, no. (% of annual total)    
 2010 8 (100) 0 8
 2011 65 (97) 2 (3) 67
 2012 129 (89.6) 15 (10.4) 144
 2013 31 (96.9) 1 (3.1) 32
 2014 66 (93) 5 (7) 71
 2015 154 (94.5) 9 (5.5) 163
 2016 178 (93.2) 13 (6.8) 191
 2017 112 (94.1) 7 (5.9) 119
Abbreviation: IQR, interquartile range.
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was against penicillin (5 of 8 isolates; all were susceptible to 
amoxicillin and ceftriaxone), followed by clarithromycin and 
doxycycline (4 of 8 each). We did not detect any levofloxacin or 
vancomycin resistance. We identified resistance to 3 antibiotic 
classes in 2 isolates and resistance to 2 classes in a further 4 iso-
lates. All resistant isolates were detected after 1 April 2015 (8 of 
28 [28.6%]), compared with 0 of 24 before this cutoff (P = .005).
DISCUSSION
We found a higher rate of colonization than has previously been 
reported in the general European adult population [1, 12]. This 
finding is notable given that the exclusion criteria for EHPC 
studies resulted in all participants lacking major risk factors for 
pneumococcal acquisition [9]. When our results are compared 
to those from a recent colonization study of United Kingdom 
children aged <5  years and their parents, we identified more 
frequent colonization and a greater range of serotypes than 
were found in the parents but less colonization and fewer sero-
types than were found in the children [4].
Although our data collection spanned the first 7  years of 
PCV13 implementation, the relative distribution of serotypes 
did not change over this time. Our colonization patterns were 
dominated by nonvaccine types, reflecting current trends in 
IPD and colonization in the United Kingdom [3, 4]. Serotype 
8 is currently the commonest cause of IPD in the United 
Kingdom and was the joint third-most frequently detected 
serotype in our study, even though it was not detected in the 
most recent United Kingdom pediatric colonization survey [3, 
4]. A cross-sectional study in 2010–2011 identified PCV13 sero-
types (specifically 3, 19F, and 19A) in 5 of 36 colonized United 
Kingdom adults [6]; we identified ongoing circulation of these 
same serotypes throughout the PCV13 era. This could explain 
why serotypes 3 and 19A remain common in IPD even though 
they are rarely identified in pediatric colonization [3, 4]. This 
reservoir in young adults could have the potential to recolonize 
the pediatric population after the United Kingdom reduces the 
childhood PCV13 schedule from 3 to 2 doses [13]. Conversely, 
the failure of the current pediatric vaccine schedule to generate 
herd protection against these serotypes could support a call for 
vaccination of at-risk adults, although the 23-valent pneumo-
coccal polysaccharide vaccine is already used for direct protec-
tion of this population in the United Kingdom.
While our study outperformed the pediatric colonization 
survey in detecting certain serotypes with invasive potential 
(eg, 3, 8, and 19A), the pediatric survey frequently identified 
carriage with invasive serotypes (eg, 15B/C and 10A) that were 
poorly represented in our cohort [4]. Therefore, it seems that 
colonization surveys should optimally include a wider range of 
subjects, rather than being restricted to households with chil-
dren. This would maximize their potential to quantify sero-
type replacement and complement IPD surveillance in guiding 
future vaccine formulation recommendations.
Colonization studies have typically focused on children and 
their close contacts, to maximize the yield from screening. We 
are aware of one other study that deliberately recruited a con-
trol cohort of adults who lacked close contact with children [8]. 
The authors detected colonization in 10% of Dutch parents (29 
of 298)  versus 2% of controls (5 of 323), using culture-based 
methods. Molecular testing increased the yield to 7% in con-
trols (21 of 323), similar to our findings, which were based on 
culture-based methods in United Kingdom adults.
Antimicrobial resistance in pneumococci is a growing global 
health concern [14]. We detected the emergence of antimicro-
bial resistance during the later period of this study, with no 
resistant isolates identified during the early period. However, a 
cross-sectional study including data from United Kingdom pri-
mary care practices in 2010 identified cases of resistant pneu-
mococcal colonization in adults, suggesting that the absence of 
resistance in the early years of our data collection may be due to 
either chance or specific local factors [1]. The resistance profiles 
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Figure 1.  Serotype distribution among subjects colonized with vaccine serotypes (left) or nonvaccine serotypes (right) before (white bars) and after (gray bars) the 5-year 
anniversary of the introduction of the 13-valent pneumococcal vaccine (PCV13) in the United Kingdom.
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of different pneumococcal serotypes in adult colonization have 
not been previously reported in the United Kingdom. Although 
our numbers are small, it is concerning that the majority of 
resistant isolates displayed resistance to >1 class of antibiotic. 
Clustering of resistance in nonvaccine types suggests that the 
childhood PCV13 program is unlikely to reduce this reservoir 
of antimicrobial resistance in the community.
The main constraint of the study is the limited demographic 
and medical history data available. However, the strict inclu-
sion criteria mandated by EHPC studies should have resulted 
in a homogeneous study population, defined by the absence of 
significant risk factors for pneumococcal colonization. Another 
limitation is that our sampling was performed in a single city. 
Culture-based colonization determination, allowing accurate 
serotyping and resistance measurement, is a strength of our 
study—molecular testing of oropharyngeal samples may have 
increased our yield but would not have allowed phenotypic con-
firmation of antimicrobial resistance [8]. Our use of nasal wash 
specimens, rather than nasal or nasopharyngeal swab spec-
imens, may have contributed to the high pneumococcal yield 
obtained in this study [15]: a study using nasal swabs in >3000 
United Kingdom adults only identified colonization in 1.8% of 
participants [1].
In summary, we described pneumococcal colonization in 
a population of adults not normally targeted by colonization 
studies, including the persistence of some PCV13 serotypes, 
epidemiologically important nonvaccine types, and emerging 
antimicrobial resistance. Inclusion of a wider sample of adults 
in colonization studies would complement ongoing surveil-
lance of IPD isolates to inform national pneumococcal vacci-
nation policies.
Supplementary Data
Supplementary materials are available at The Journal of 
Infectious Diseases online. Consisting of data provided by 
the authors to benefit the reader, the posted materials are not 
copyedited and are the sole responsibility of the authors, so 
questions or comments should be addressed to the corre-
sponding author.
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